BTAI
Income statement / Annual
Last year (2023), BioXcel Therapeutics, Inc.'s total revenue was $1.38 M,
an increase of 268.00% from the previous year.
In 2023, BioXcel Therapeutics, Inc.'s net income was -$179.05 M.
See BioXcel Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.38 M
|
$375,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.26 M |
$20,000.00 |
$297,000.00 |
$188,000.00 |
$156,000.00 |
$17,000.00 |
$1,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
$120,000.00 |
$355,000.00 |
-$297,000.00 |
-$188,000.00 |
-$156,000.00 |
-$17,000.00 |
-$1,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.09 |
0.95 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$84.33 M
|
$91.24 M
|
$52.71 M
|
$58.00 M
|
$25.80 M
|
$14.56 M
|
$2.69 M
|
$1.40 M
|
$233,000.00
|
| General & Administrative
Expenses |
$63.51 M
|
$68.76 M
|
$54.23 M
|
$24.30 M
|
$7.80 M
|
$5.40 M
|
$1.85 M
|
$721,000.00
|
$0.00
|
| Selling & Marketing
Expenses |
$19.90 M
|
$13.01 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$83.41 M
|
$68.76 M
|
$54.23 M
|
$24.30 M
|
$7.80 M
|
$5.40 M
|
$1.85 M
|
$721,000.00
|
$403,000.00
|
| Other Expenses |
$4.16 M |
-$427,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$171.90 M |
$160.00 M |
$106.94 M |
$82.30 M |
$33.60 M |
$19.96 M |
$4.54 M |
$2.12 M |
$636,000.00 |
| Cost And Expenses |
$173.16 M |
$160.02 M |
$106.94 M |
$82.30 M |
$33.60 M |
$19.96 M |
$4.54 M |
$2.12 M |
$636,000.00 |
| Interest Income |
$5.65 M |
$2.53 M |
$4,000.00 |
$155,000.00 |
$633,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$13.31 M |
$8.21 M |
$40,000.00 |
$27,000.00 |
$0.00 |
$0.00 |
$2,000.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$318,000.00
|
$327,000.00
|
$297,000.00
|
$188,000.00
|
$156,000.00
|
$17,000.00
|
$1,000.00
|
$2.12 M
|
$0.00
|
| EBITDA |
-$165.42 M
|
-$157.38 M
|
-$107.00 M
|
-$81.98 M
|
-$32.81 M
|
-$19.25 M
|
-$4.54 M
|
$0.00
|
-$636,000.00
|
| EBITDA Ratio |
-119.87 |
-420.12 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-124.48
|
-425.72
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$7.27 M
|
-$6.11 M
|
-$358,000.00
|
$128,000.00
|
$633,000.00
|
$692,000.00
|
-$2,000.00
|
$0.00
|
$0.00
|
| Income Before Tax |
-$179.05 M |
-$165.76 M |
-$106.93 M |
-$82.17 M |
-$32.97 M |
-$19.27 M |
-$4.54 M |
-$2.12 M |
-$636,000.00 |
| Income Before Tax Ratio
|
-129.75
|
-442.02
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$6.09 M |
-$301,000.00 |
-$161,000.00 |
-$633,000.00 |
$692,000.00 |
$0.00 |
-$2.12 M |
$0.00 |
| Net Income |
-$179.05 M |
-$171.85 M |
-$106.63 M |
-$82.01 M |
-$32.34 M |
-$19.27 M |
-$4.54 M |
-$2.12 M |
-$636,000.00 |
| Net Income Ratio |
-129.75 |
-458.26 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-6.15 |
-6.13 |
-4.04 |
-3.78 |
-1.99 |
-1.32 |
-0.3 |
-0.14 |
-0.0399 |
| EPS Diluted |
-6.15 |
-6.13 |
-4.04 |
-3.78 |
-1.99 |
-1.32 |
-0.3 |
-0.14 |
-0.0399 |
| Weighted Average Shares
Out |
$29.13 M
|
$28.02 M
|
$26.37 M
|
$21.68 M
|
$16.29 M
|
$14.57 M
|
$15.19 M
|
$15.65 M
|
$15.94 M
|
| Weighted Average Shares
Out Diluted |
$29.13 M
|
$28.02 M
|
$26.37 M
|
$21.68 M
|
$16.29 M
|
$14.57 M
|
$15.19 M
|
$15.65 M
|
$15.94 M
|
| Link |
|
|
|
|
|
|
|
|
|
